BioArctic in 15 seconds
BioArctic is a Swedish research-based biopharmaceutical company focused on the innovation of drugs that can delay or stop the progression of neurodegenerative diseases. The company is behind lecanemab (Leqembi®)–the world’s first drug proven to slow disease progression and reduce cognitive decline in early Alzheimer’s disease. Lecanemab has been developed in collaboration with Eisai. BioArctic has a broad research portfolio in Alzheimer’s disease, Parkinson’s disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company’s proprietary technology platform BrainTransporter™, which improves the transport of drugs into the brain. The unique BrainTransporter technology enables a more efficient transport of selective antibodies into the brain, and with significantly higher concentrations than has previously been possible. The BioArctic share is traded on Nasdaq Stockholm’s Large Cap under the symbol BIOA B.
-
2003
BioArctic is founded
-
2
Technology platforms
-
107
Employees
CEO statement
“2024 was yet another transformative year for BioArctic. With a another billion-krona deal signed with a global pharmaceutical company, major advances for our BrainTransporter technology, continued launch of Leqembi and the Phase 2a study of exidavnemab in Parkinson’s disease in full swing, we have entered a new era. We are now a company that has demonstrated the potential of two groundbreaking innovations: our antibodies and our BrainTransporter technology. Together, these innovations create unique opportunities to help patients with neurodegenerative diseases, while contributing to future value creation for BioArctic’s shareholders.
Gunilla Osswald, CEO BioArctic
BioArctic in numbers 2024
-
257
Net revenue, SEK M
-
230
Royalties, SEK M
-
779
Cash and cash equivalents and current investments, SEK M
-
- 229
Operating loss, SEK M
-
≈ 900
Remaining milestone payments from Eisai as of December 31, 2024, SEK M
-
≈ 13.5
Contract value Bristol Myers Squibb, Billion SEK
Vision
A world in which we successfully stop the onset of neurodegenerative diseases
Mission
Together, we generate, develop, and provide drugs of the future for patients with severe neurodegenerative diseases and other conditions with significant medical needs.
BioArctic’s antibodies
BioArctic specializes in developing selective antibodies against aggregations of misfolded proteins in the central nervous system. Our research has resulted in lecanemab, the world’s first fully approved disease-modifying drug against Alzheimer’s disease, which is now being offered to patients in large parts of the world. Based on this same principle, BioArctic has built up a broad project portfolio with selective antibodies not only to treat Alzheimer’s disease but also antibodies with the potential to slow the progression of Parkinson’s disease and other synucleinopathies as well as ALS.
Alzheimer’s disease
BioArctic is the originator of Leqembi (lecanemab), the world’s first drug shown to slow down the progression of and reduce cognitive decline in early Alzheimer’s disease.
Parkinson’s disease
BioArctic’s antibodies for misfolded alpha-synuklein have the potential to become effective disease-modifying treatments for Parkinson’s disease and other synucleinopathies.
ALS
By using unique antibodies against the TDP-43 protein, BioArctic hopes to develop a drug that treats the underlying cause of ALS, with the potential to slow down the progress of the disease.
The BrainTransporter technology
There is still great untapped potential for biological drugs against diseases in the brain. Development has been held back by the difficulties in getting these types of drugs into the brain, since the blood-brain barrier obstructs their passage. BioArctic’s BrainTransporter technology facilitates the active transport of antibodies into the brain. This breakthrough opens up entirely new possibilities for developing effective drugs against diseases that currently lack treatments. In 2024, BioArctic was able to present validating preclinical results for its BrainTransporter technology, which shows that the company is on the way to solving one of the greatest challenges in the development of new drugs against diseases of the central nervous system.
BioArctic ready for launch in the Nordic region
BioArctic has gradually built up a strong organization with a presence in all the Nordic countries, and is now ready for the next phase of the introduction of Leqembi, after EU approval in April 2025. The commercialization of the therapy in Sweden, Finland, Denmark, Norway and Iceland will be done in partnership with Eisai.
With a focus on the next partnership
In December 2024, a new license agreement was signed with Bristol Myers Squibb, with a contract value of up to USD 1.35 billion plus royalties. BioArctic is continuing intensive dialogues with potential partners, focusing on its BrainTransporter technology and exidavnemab.
Sustainability – a natural part of BioArctic
BioArctic’s foremost contribution to a global sustainable future is the development of drugs to prevent and treat diseases of the brain, with the goal of improving life for affected patients and their families. This view on sustainability is deeply rooted into the organization and our daily activities in order to ensure a sustainable future for the patients we are helping, as well as for our employees and our shareholders. We conduct responsible research of the highest scientific quality, which presupposes that we are a responsible and attractive employer.
Continued growth
The successes with lecanemab against Alzheimer’s disease make a strong foundation for BioArctic’s continued growth. With a broad portfolio, promising results for the BrainTransporter technology, the organization is expanding to make use of all possibilities and prepare for the launch of Leqembi in the Nordic region. At the same time, discussions with potential new partners are intensifying.
The BioArctic share
The BioArctic share is traded on Nasdaq Stockholm’s Large Cap under the symbol BIOA B. The company’s market value at year end totaled SEK 17.6 billion.The highest price paid, SEK 288.40, was noted on January 9, 2024, and the lowest price, SEK 137.70, was noted on November 8, 2024. At year-end, BioArctic had 23,833 shareholders (20,697).
Historic share price performance
Share price trends and volume 2024
